Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. Fundamental Analysis
Aquestive Therapeutics, Inc. (AQST) shows moderate financial fundamentals with a PE ratio of -6.35, profit margin of -1.59%, and ROE of 1.40%. The company generates $0.0B in annual revenue with strong year-over-year growth of 13.80%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 257.5/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze AQST's fundamental strength across five key dimensions:
Efficiency Score
WeakAQST struggles to generate sufficient returns from assets.
Valuation Score
ModerateAQST shows balanced valuation metrics.
Growth Score
ModerateAQST shows steady but slowing expansion.
Financial Health Score
ExcellentAQST maintains a strong and stable balance sheet.
Profitability Score
WeakAQST struggles to sustain strong margins.
Key Financial Metrics
Is AQST Expensive or Cheap?
P/E Ratio
AQST trades at -6.35 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, AQST's PEG of 4.44 indicates potential overvaluation.
Price to Book
The market values Aquestive Therapeutics, Inc. at -106.55 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -8.09 times EBITDA. This is generally considered low.
How Well Does AQST Make Money?
Net Profit Margin
For every $100 in sales, Aquestive Therapeutics, Inc. keeps $-1.59 as profit after all expenses.
Operating Margin
Core operations generate -1.29 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.40 in profit for every $100 of shareholder equity.
ROA
Aquestive Therapeutics, Inc. generates $-42.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Aquestive Therapeutics, Inc. generates limited operating cash flow of $-45.31M, signaling weaker underlying cash strength.
Free Cash Flow
Aquestive Therapeutics, Inc. generates weak or negative free cash flow of $-45.75M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.46 in free cash annually.
FCF Yield
AQST converts -12.94% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-6.35
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
4.44
vs 25 benchmark
P/B Ratio
Price to book value ratio
-106.55
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.06
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-31.36
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.93
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
1.40
vs 25 benchmark
ROA
Return on assets percentage
-0.42
vs 25 benchmark
ROCE
Return on capital employed
-0.40
vs 25 benchmark
How AQST Stacks Against Its Sector Peers
| Metric | AQST Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -6.35 | 29.43 | Better (Cheaper) |
| ROE | 139.50% | 800.00% | Weak |
| Net Margin | -158.95% | -20145.00% (disorted) | Weak |
| Debt/Equity | -31.36 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 5.93 | 4.64 | Strong Liquidity |
| ROA | -42.17% | -17936.00% (disorted) | Weak |
AQST outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Aquestive Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-68.01%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
80.52%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
82.64%
Industry Style: Defensive, Growth, Innovation
High Growth